EDP Sciences logo
Authentification abonné
rechercher
Menu
Accueil Tous les numéros Thérapie, 60 4 (2005) 419-422 Article's citations

Article cité par

La fonctionnalité Article cité par… liste les citations d'un article. Ces citations proviennent de la base de données des articles de EDP Sciences, ainsi que des bases de données d'autres éditeurs participant au programme CrossRef Cited-by Linking Program. Vous pouvez définir une alerte courriel pour être prévenu de la parution d'un nouvel article citant " cet article (voir sur la page du résumé de l'article le menu à droite).

Article cité :

Interest of hair tests to discriminate a tail end of a doping regimen from a possible contamination in case of challenging an anti‐doping rule violation. V. Case reports involving trimetazidine, a drug where the concentration after a single 20 mg dose has been established

Pascal Kintz, Alice Ameline and Laurie Gheddar
Drug Testing and Analysis 17 (6) 779 (2025)
https://doi.org/10.1002/dta.3775

No fault or negligence after an adverse analytical finding due to a contaminated supplement: mission impossible. Two examples involving trimetazidine

Pascal Kintz
Clinical Chemistry and Laboratory Medicine (CCLM) (2025)
https://doi.org/10.1515/cclm-2025-0549

Eduard Bezuglov, Maria Shoshorina, Andrey Zholinsky, Zbigniew Waśkiewicz, Anton Emanov, Ryland Morgans, Vladislav Bertholz, Vasilisa Zelenskaya, Artemii Lazarev, Maria Sokolskaya and Oleg Talibov
(2022)
https://doi.org/10.1101/2022.05.09.22274810

Effectiveness of Trimetazidine in Patients with Chronic Heart Failure Stratified by the Expression of Soluble Suppression of Tumorigenicity-2 (sST2): A Prospective Cohort Study

Zhu Min, Liu Xuelu, Zhang Ran, Shu Qiuhong and Meng Yong
Advances in Therapy 39 (12) 5514 (2022)
https://doi.org/10.1007/s12325-022-02315-x

Trimetazidine Use in Parkinson’s Disease: Is It a Resolved Problem?

Dávid Pintér, Dániel Bereczki, András Ajtay, Ferenc Oberfrank, József Janszky and Norbert Kovács
eneuro 8 (3) ENEURO.0452-20.2021 (2021)
https://doi.org/10.1523/ENEURO.0452-20.2021

The Inclusion in WADA Prohibited List Is Not Always Supported by Scientific Evidence: A Narrative Review

Eduard Bezuglov, Oleg Talibov, Mikhail Butovskiy, et al.
Asian Journal of Sports Medicine 12 (2) (2021)
https://doi.org/10.5812/asjsm.110753

The Impact of Trimetazidine on Disease Severity and Quality of Life in Parkinson’s Disease

Dávid Pintér, Annamária Juhász, Márk Harmat, József Janszky and Norbert Kovács
Scientific Reports 10 (1) (2020)
https://doi.org/10.1038/s41598-020-66692-5

Trimetazidine Use and the Risk of Parkinsonism: A Nationwide Population-Based Study

Seungyeon Kim, Yun Mi Yu, Jeongyoon Kwon, Kyeong Hye Jeong, Jeong Sang Lee and Euni Lee
International Journal of Environmental Research and Public Health 17 (19) 7256 (2020)
https://doi.org/10.3390/ijerph17197256

Cinnarizine- and flunarizine-associated movement disorder: a literature review

Jamir Pitton Rissardo and Ana Letícia Fornari Caprara
The Egyptian Journal of Neurology, Psychiatry and Neurosurgery 56 (1) (2020)
https://doi.org/10.1186/s41983-020-00197-w

Trimetazidine-Induced Parkinsonism: A Systematic Review

Anna Marielle B. Dy, Lorenzo Luis G. Limjoco and Roland Dominic G. Jamora
Frontiers in Neurology 11 (2020)
https://doi.org/10.3389/fneur.2020.00044

La trimétazidine (Vastarel) est-elle un produit dopant ? Proposition pour une suppression de la liste des produits interdits de l’Agence mondiale anti-dopage

Pascal Kintz
Toxicologie Analytique et Clinique 32 (4) 239 (2020)
https://doi.org/10.1016/j.toxac.2020.09.079

Evidence of Repurposing Drugs and Identifying Contraindications from Real World Study in Parkinson’s Disease

Yilin Tang, Ke Yang, Jue Zhao, Xiaoniu Liang and Jian Wang
ACS Chemical Neuroscience 10 (2) 954 (2019)
https://doi.org/10.1021/acschemneuro.8b00456

Trimetazidine and parkinsonism: A prospective study

Dávid Pintér, Márton Kovács, Márk Harmat, Annamária Juhász, József Janszky and Norbert Kovács
Parkinsonism & Related Disorders 62 117 (2019)
https://doi.org/10.1016/j.parkreldis.2019.01.005

Extra energy for hearts with a genetic defect: ENERGY trial

B. O. van Driel, A. C. van Rossum, M. Michels, R. Huurman and J. van der Velden
Netherlands Heart Journal 27 (4) 200 (2019)
https://doi.org/10.1007/s12471-019-1239-0

Cardiac metabolism — A promising therapeutic target for heart failure

Hannah Noordali, Brodie L. Loudon, Michael P. Frenneaux and Melanie Madhani
Pharmacology & Therapeutics 182 95 (2018)
https://doi.org/10.1016/j.pharmthera.2017.08.001

Mesenchymal stem cells in cardiac regeneration: a detailed progress report of the last 6 years (2010–2015)

Aastha Singh, Abhishek Singh and Dwaipayan Sen
Stem Cell Research & Therapy 7 (1) (2016)
https://doi.org/10.1186/s13287-016-0341-0

Doping control analysis of trimetazidine and characterization of major metabolites using mass spectrometric approaches

Gerd Sigmund, Anja Koch, Anne‐Katrin Orlovius, Sven Guddat, Andreas Thomas, Wilhelm Schänzer and Mario Thevis
Drug Testing and Analysis 6 (11-12) 1197 (2014)
https://doi.org/10.1002/dta.1680

The prevalence of trimetazidine use in athletes in Poland: excretion study after oral drug administration

Anna Jarek, Marzena Wójtowicz, Dorota Kwiatkowska, Monika Kita, Ewa Turek‐Lepa, Katarzyna Chajewska, Sylwia Lewandowska‐Pachecka and Andrzej Pokrywka
Drug Testing and Analysis 6 (11-12) 1191 (2014)
https://doi.org/10.1002/dta.1755

Defining the Role of Trimetazidine in the Treatment of Cardiovascular Disorders: Some Insights on Its Role in Heart Failure and Peripheral Artery Disease

Piotr Chrusciel, Jacek Rysz and Maciej Banach
Drugs 74 (9) 971 (2014)
https://doi.org/10.1007/s40265-014-0233-5

Taking Diabetes to Heart—Deregulation of Myocardial Lipid Metabolism in Diabetic Cardiomyopathy

Marina Bayeva, Konrad Teodor Sawicki and Hossein Ardehali
Journal of the American Heart Association 2 (6) (2013)
https://doi.org/10.1161/JAHA.113.000433

Utilidad de la tomografía por emisión de fotón simple con 123Ioflupano en el diagnóstico del parkinsonismo relacionado con fármacos. Estudio prospectivo

J. Olivares Romero and A. Arjona Padillo
Neurología 28 (5) 276 (2013)
https://doi.org/10.1016/j.nrl.2012.05.005

Antipsychotic‐Like Effect of Trimetazidine in a Rodent Model

Oytun Erbaş, Hüseyin Serdar Akseki, Betül Eliküçük, Dilek Taşkıran, N. Berretta, J. L. Labandeira-García, A. Takano and Y. Yoshiyama
The Scientific World Journal 2013 (1) (2013)
https://doi.org/10.1155/2013/686304

Diagnostic accuracy of 123I-FP-CIT SPECT in diagnosing drug-induced parkinsonism: A prospective study

J. Olivares Romero and A. Arjona Padillo
Neurología (English Edition) 28 (5) 276 (2013)
https://doi.org/10.1016/j.nrleng.2012.05.007

Extrapyramidal adverse drug reactions associated with trimetazidine: a series of 21 cases

Kamel Masmoudi, Henri Masson, Valérie Gras and Michel Andréjak
Fundamental & Clinical Pharmacology 26 (2) 198 (2012)
https://doi.org/10.1111/j.1472-8206.2011.01008.x

Drug‐induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France

Emmanuelle Bondon‐Guitton, Santiago Perez‐Lloret, Haleh Bagheri, Christine Brefel, Olivier Rascol and Jean‐Louis Montastruc
Movement Disorders 26 (12) 2226 (2011)
https://doi.org/10.1002/mds.23828

Trimetazidine Revisited: A Comprehensive Review of the Pharmacological Effects and Analytical Techniques for the Determination of Trimetazidine

A. Onay‐Besikci and S.A. Özkan
Cardiovascular Therapeutics 26 (2) 147 (2008)
https://doi.org/10.1111/j.1527-3466.2008.00043.x

Encéphalopathie avec mouvements choréiformes induits par la trimétazidine : à propos d’un cas

J. Sivet, B. de la Gastine, B. Mosquet, et al.
La Revue de Médecine Interne 29 (6) 512 (2008)
https://doi.org/10.1016/j.revmed.2007.12.001

Structure–activity studies on the protection of Trimetazidine derivatives modified with nitroxides and their precursors from myocardial ischemia–reperfusion injury

Tamás Kálai, Mahmood Khan, Mária Balog, et al.
Bioorganic & Medicinal Chemistry 14 (16) 5510 (2006)
https://doi.org/10.1016/j.bmc.2006.04.040